Aethlon Medical
Aethlon Medical develops immunotherapeutic technologies to combat cancer and infectious disease. Their flagship product, the Hemopurifier®, is a first-in-class device designed for rapid depletion of cancer-promoting exosomes and circulating viruses. Recognized as a 'Breakthrough Device' by the FDA, the company is conducting clinical trials for its Hemopurifier® in cancer patients with solid tumors and is involved in collaborations to develop diagnostic tools for conditions like CTE in former NFL players. The company's mission is to address unmet therapeutic needs in infectious disease, cancer, and neurodegenerative disorders through targeted medical devices.
Industries
Nr. of Employees
small (1-50)
Aethlon Medical
Patents
Products
Extracorporeal affinity-filtration therapeutic device for depletion of circulating exosomes and viruses
A first-in-class extracorporeal therapeutic platform designed to selectively remove circulating exosomes and blood-borne viruses from patient plasma with the objective of augmenting immune response or treating life-threatening viral infections.
Hemopurifier
An investigational extracorporeal medical device designed for the broad-spectrum capture and clearance of life-threatening viruses and pathogens from the circulatory system.
Extracorporeal affinity-filtration therapeutic device for depletion of circulating exosomes and viruses
A first-in-class extracorporeal therapeutic platform designed to selectively remove circulating exosomes and blood-borne viruses from patient plasma with the objective of augmenting immune response or treating life-threatening viral infections.
Hemopurifier
An investigational extracorporeal medical device designed for the broad-spectrum capture and clearance of life-threatening viruses and pathogens from the circulatory system.
Services
Sponsor-led clinical trials assessing safety and dose parameters of extracorporeal therapeutic devices in oncology and infectious disease populations, including multi-country trial execution.
R&D and translational development of blood-based exosome assays for biomarker detection in oncology, infectious disease and neurodegenerative indications.
Sponsor-led clinical trials assessing safety and dose parameters of extracorporeal therapeutic devices in oncology and infectious disease populations, including multi-country trial execution.
R&D and translational development of blood-based exosome assays for biomarker detection in oncology, infectious disease and neurodegenerative indications.
Expertise Areas
- Extracorporeal blood purification
- Clinical trial management (safety, feasibility, dose-finding)
- Exosome-based diagnostics and biomarker discovery
- Device development and translational R&D
Key Technologies
- Affinity-based adsorption cartridges
- Extracorporeal filtration platforms
- Exosome isolation and analysis
- Surface-enhanced Raman spectroscopy (SERS) and advanced sensing